Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice

Abstract

Necroptosis contributes to necroptotic cell death and influences functional outcome after SCI in adult mice. The inhibition of necroptosis by necrostatin-1 may have therapeutic potential for patients with SCI.

Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment

“…However, emerging evidence has shown that necrosis can be induced and regulated in a similar manner to apoptosis. This has been recently identified as a form of programmed cell death that is different with traditional necrosis and apoptosis [124, 125]. Furthermore, it is a regulated cell death with the morphological characterization of necrosis; which can be pharmacologically inhibited by certain chemical compounds such as necrostatin-1 [126].…”

Acute administration of ucf-101 ameliorates the locomotor impairments induced by a traumatic spinal cord injury

“…Neural cell death plays a key role in this complex pathology and significantly contributes to the final extent of the neural damage (Grossman et al, 2001). In the following hours and days, apoptosis and other forms of programmed cell death (for example necroptosis, autophagic, parthanatos) gradually replace necrosis (Bianchetti et al, 2013;Crowe et al, 1997;Grossman et al, 2001;Kanno et al, 2011;Liu et al, 2014Liu et al, , 1997Lou et al, 1998). During the next days, there is a reduction of the programmed cell death in the impact region (Liu et al, 1997;Lou et al, 1998) followed by a second wave of cell death that affects the white matter away from the impact epicenter (Abe et al, 1999).…”

The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease

“…Recent reports associated the activation of necroptosis to several neurodegenerative conditions (reviewed in Yuan et al, 2019). Inhibition of necroptosis with small molecules or genetic ablation of RIPK1, RIPK3 or MLKL exert neuroprotective effects in models of brain damage, including ischemia (Qu et al, 2016;Yin et al, 2015;Zhang et al, 2016b), traumatic injury (You et al, 2008), viral infections (Bian et al, 2017), in addition to contribute to retinal damage (Dong et al, 2012;Kim et al, 2016;Viringipurampeer et al, 2014) and spinal cord injury (Liu et al, 2015). Recent advances in the field have demonstrated the therapeutic potential of inhibiting necroptosis in several neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) (Ito et al, 2016;Re et al, 2014) multiple sclerosis (MS) (Ofengeim et al, 2015) and Alzheimer's disease (AD) (Caccamo et al, 2017).…”